Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06537960

Interest of Late Images for the Assessment of Extensions in 18FDG PET-CT of Muscle-Invasive Bladder Cancers

Led by Hopital Foch · Updated on 2025-11-21

66

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of late-phase 18FDG PET-CT imaging to improve lymph node staging in patients with muscle-invasive bladder tumor (MIBT) at stage 63pT2. This study aims to show whether delayed PET images taken 2.5 hours after radiotracer injection offer better sensitivity compared to the standard images taken at 1 hour. The assessment focuses on areas around the right and left iliac lymph nodes to guide treatment decisions for these patients. Participants will undergo 18FDG PET-CT scans in two phases: the first phase involves a standard scan from head to mid-thigh at 1 hour after injection of the radiotracer and a diuretic, with a CT scan for anatomical details. The second phase consists of additional abdomino-pelvic scans at 2.5 hours post-injection with a low-dose CT scan for correction purposes. Patients will empty their bladder before each scan phase to improve image quality. During the study, patients will receive routine care including fasting and blood glucose checks before imaging. Researchers will compare PET scan findings with lymph node removal results after surgery (if performed) to measure sensitivity. Treatment decisions will be made based on standard PET images, while late images will be analyzed later for sensitivity. Participants may be followed for up to 39 months to assess outcomes related to lymph node staging.

CONDITIONS

Brief Title

Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient 18 years of age or older
  • Histologically proven muscle-invasive bladder cancer (stage 63pT2) after bladder resection
  • Scheduled for 18FDG PET-CT at H�f4pital Foch nuclear medicine department
  • Signed informed consent form
  • Affiliated with a health insurance scheme
Not Eligible

You will not qualify if you...

  • History of pelvic or genitourinary cancer
  • Known metastatic disease
  • Contraindication to 18FDG PET-CT
  • Pregnant or breastfeeding women
  • Patients deprived of liberty or under guardianship

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Same day

Participants undergo 18FDG PET-CT imaging in two phases to assess bladder cancer extensions.

1 visit (in-person) with imaging at 1 hour and 2.5 hours post radiotracer injection

Trial Site Locations

Total: 1 location

1

Hopital Foch

Suresnes, Île-de-France Region, France, 92150

Actively Recruiting

Loading map...

Research Team

M

MARC BERTAUX, Dr

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A Phase 1/2 Open Label, Dose Escalation and Expansion Study ...

Advanced Solid Tumor

Actively Recruiting

27 locations

Bladder-Sparing Treatment Strategies Versus Radical Cystecto...

Bladder Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here